Silicon Valley Capital Partners Has $16.18 Million Stock Position in Eli Lilly and Company $LLY

Silicon Valley Capital Partners boosted its position in Eli Lilly and Company (NYSE:LLY) by 3.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,489 shares of the company’s stock after acquiring an additional 480 shares during the period. Eli Lilly and Company accounts for about 1.5% of Silicon Valley Capital Partners’ holdings, making the stock its 19th biggest position. Silicon Valley Capital Partners’ holdings in Eli Lilly and Company were worth $16,179,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Mosaic Family Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after acquiring an additional 1,430 shares in the last quarter. Generali Investments Management Co LLC grew its holdings in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after acquiring an additional 1,521 shares in the last quarter. Moran Wealth Management LLC increased its position in shares of Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after acquiring an additional 9,638 shares during the last quarter. Finally, Amundi increased its position in shares of Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after acquiring an additional 454,549 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Citigroup boosted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, September 9th. Leerink Partners lifted their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Morgan Stanley reissued an “overweight” rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,305.25.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Approximately 700,000 seniors have started GLP-1 treatments since new Medicare coverage began in July, and about 70% are using Eli Lilly medicines. The data suggests Medicare could materially expand the company’s addressable obesity-treatment market. Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage
• Positive Sentiment: CEO David Ricks said roughly one-third of newly prescribed GLP-1 pills are Lilly’s Foundayo, prompting the company to increase production. Strong early adoption supports the outlook for Lilly’s oral obesity-drug franchise. Lilly is ramping up future manufacturing for Foundayo obesity pill
• Positive Sentiment: Lilly is breaking ground on a planned $6.5 billion Houston manufacturing facility, reinforcing management’s confidence in long-term demand and expanding capacity for future medicines. Eli Lilly to host groundbreaking of $6.5 billion facility
• Neutral Sentiment: A completed early-stage study of LY3971297 moves Lilly’s cardio-metabolic pipeline toward the next development steps, but no efficacy or safety results were reported, limiting the immediate investment impact. Eli Lilly’s LY3971297 trial completion
• Neutral Sentiment: Commentary noted that Lilly’s revenue is growing rapidly while the stock has been comparatively weak this year, suggesting investors may be discounting valuation, competition, or the sustainability of GLP-1 growth.
• Negative Sentiment: Investor concerns about Novo Nordisk’s pipeline intensified after data indicated its CagriSema combination outperformed Lilly’s tirzepatide in a weight-loss trial. The development underscores increasing competitive risk in Lilly’s core obesity market. Novo Nordisk falls as competition concerns persist

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $12.69 on Monday, hitting $1,165.62. 2,232,094 shares of the stock traded hands, compared to its average volume of 3,023,233. The business’s fifty day moving average is $1,176.90 and its two-hundred day moving average is $1,077.21. Eli Lilly and Company has a 12 month low of $712.05 and a 12 month high of $1,292.65. The firm has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.11, a PEG ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the business posted $6.31 earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 36.54 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.